Co-Diagnostics’ (CODX) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Co-Diagnostics (NASDAQ:CODX) in a research report released on Tuesday,Benzinga reports. The firm currently has a $3.00 price target on the stock.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Co-Diagnostics in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $2.00.

Co-Diagnostics Stock Performance

Shares of Co-Diagnostics stock opened at $0.57 on Tuesday. The company’s 50 day moving average is $0.38 and its 200 day moving average is $0.32. Co-Diagnostics has a twelve month low of $0.23 and a twelve month high of $1.55.

Co-Diagnostics (NASDAQ:CODX) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. The company had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.30 million. Co-Diagnostics had a negative net margin of 3,588.33% and a negative return on equity of 69.49%. Equities analysts expect that Co-Diagnostics will post -1.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Co-Diagnostics

An institutional investor recently raised its position in Co-Diagnostics stock. Jane Street Group LLC boosted its position in shares of Co-Diagnostics, Inc. (NASDAQ:CODX) by 314.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 166,254 shares of the company’s stock after acquiring an additional 126,105 shares during the period. Jane Street Group LLC owned 0.50% of Co-Diagnostics worth $47,000 at the end of the most recent quarter. Institutional investors and hedge funds own 14.99% of the company’s stock.

Co-Diagnostics Company Profile

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.